Aurinia Pharmaceuticals Inc (AUPH)

AUPH (NASDAQ:Drugs) EQUITY
$7.00
neg -0.30
-4.10%
Today's Range: 6.93 - 7.35 | AUPH Avg Daily Volume: 8,259,600
Last Update: 03/30/17 - 3:59 PM EDT
Volume: 5,139,694
YTD Performance: 247.62%
Open: $7.35
Previous Close: $7.30
52 Week Range: $1.42 - $4.30
Oustanding Shares: 78,453,235
Market Cap: 561,725,163
6-Month Chart
TheStreet Ratings Grade for AUPH
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 4 4 4 4
Moderate Buy 0 0 0 0
Hold 1 1 1 1
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.26 1.26 1.26 1.26
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: -10.85
Price Earnings Comparisons:
AUPH Sector Avg. S&P 500
-10.85 0.00 30.50
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
239.53% 144.16% 137.48%
GROWTH 12 Mo 3 Yr CAGR
Revenue -15.50 -1.00 -0.66
Net Income 0.00 0.90 0.00
EPS 0.00 -0.80 0.00
Earnings for AUPH:
EBITDA -0.02B
Revenue 0.00B
Average Earnings Estimates
Qtr (03/17) Qtr (06/17) FY (12/17) FY (12/18)
Average Estimate $-0.11 $-0.11 $-0.44 $-0.47
Number of Analysts 4 4 4 3
High Estimate $-0.08 $-0.08 $-0.33 $-0.33
Low Estimate $-0.13 $-0.12 $-0.49 $-0.59
Prior Year $-0.13 $-0.14 $-0.69 $-0.44
Growth Rate (Year over Year) 19.23% 25.00% 36.59% -8.19%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
But what will be most important is whether support stays strong and the buyers show interest in the afternoon.
Why not buy something and try to make some money rather than waste time predicting how this will all come to an ugly end?
Biotech companies show more energy than the rest of the market Monday.
Trading radar isn't picking up much that's worthwhile.
Not making any new buys, but I haven't rushed to make sales either.
U.S. stocks saw slow action ahead of the start of a Fed meeting and a big East Coast snow storm Tuesday.
This group has had some excellent speculative action lately while not much else has been working.
The markets' focus will be on the pace of future interest rate hikes.
We end the week with the same question we had at the start.
Biotechnology continues to be a bright spot.

Columnist Conversations

The DJIA has been making lows at a fairly regular interval of 101 days. The cycle tools overlaid on the daily ...
this stock continues to move well, momentum is strong. BOUGHT JACK MAY 100 CALL AT 5.25
I have a special guest joining me today, legendary technician Marc Chaikin comes aboard tonight, talking about...
View Chart »  View in New Window » To fail or not to fail is the question.  The video I d...

REAL MONEY'S BEST IDEAS

News Breaks

Powered by

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.